Skip to main content

Table 4 Sensitivity analysis for the imput parameters on ICER and Cost-Benefit

From: Cost-effectiveness of different human papillomavirus vaccines in Singapore

Parameters ICER (SGD/LY saved), discounted ICER (SGD/QALY saved), discounted Cost Benefit Analysis (million SGD), discounted
  Quadrivalent vaccine vs No vaccine Bivalent vaccine vs No vaccine Bivalent vaccine vs Quadrivalent vaccine Quadrivalent vaccine vs No vaccine Bivalent vaccine vs No vaccine Bivalent vaccine vs Quadrivalent vaccine Quadrivalent vaccine vs No vaccine Bivalent vaccine vs No vaccine Bivalent vaccine vs Quadrivalent vaccine
Base case 12,866 12,827 12,488 9,071 10,392 Dom 8.23 9.47 1.24
Vaccine coverage (base:100%) - assuming vaccine purchase costs for the cohort are sunk costs
   20% 86,397 83,454 56,178 61,804 67,631 Dom -6.25 -6.57 -0.33
   40% 40,444 39,322 29,109 28,847 31,864 Dom -2.72 -2.75 -0.03
   60% 25,124 24,607 19,981 17,861 19,938 Dom 0.92 1.21 0.29
   80% 17,464 17,246 15,337 12,367 13,973 Dom 4.67 5.23 0.63
Vaccine coverage (base:100%) - assuming vaccine costs are as consumed
   20% 11,524 15,873 56,178 8,059 12,818 Dom 1.75 1.43 -0.33
   40% 12,804 14,417 29,109 9,010 11,668 Dom 3.38 3.25 -0.03
   60% 13,034 13,733 19,981 9,166 10,727 Dom 4,92 5.21 0.29
   80% 13,003 13,241 15,337 9,185 11,122 Dom 6,67 7.3 0.63
Vaccine efficacy (Bivalent base: 88.3%, Quadrivalent base: 79.4%)
   70% 15,008 17,237 Dom 10,369 13,894 Dom 6.43 5.31 -1.11
   90% 10,863 12,326 Dom 7,733 9,932 Dom 11.13 10.17 -0.96
Vaccination costs (base: SGD$400 for both)
   Decrease to SGD$300 for both 8,521 8,942 12,572 5,922 7,205 Dom 10.96 11.96 1
   Decrease to SGD$200 for both, 4,109 4,988 12,572 2,775 4,019 Dom 13.46 14.46 1
   Decrease to SGD$100 for both Dom 1,034 12,572 Dom 833 Dom 15.96 16.96 1
Booster (base: none)
   5 years 91,149 83,707 19,486 67,830 70,487 Dom -36.07 -35.52 0.54
   10 years 47,045 43,778 15,584 36,192 38,134 Dom -10.94 -10.14 0.8
   20 years 27,321 26,048 15,067 19,483 21,093 Dom 0.3 1.13 0.84
Screening coverage rate (base: 17%)      
   10% 12,424 12,398 12,171 9,120 10,409 Dom 9.2 10.29 1.08
   25% 13,670 13,558 12,593 9,199 10,552 Dom 7.68 8.63 0.95
   40% 15,200 14,845 11,783 9,628 10,977 Dom 6.43 7.35 0.92
Effectiveness against viral warts      
   70% 13,348 12,827 8,996 9,665 10,392 57,447 8.23 9.46 1.23
   80% 13,143 12,827 10,768 9,366 10,392 640,633 8.35 9.46 1.11
   100% 12,721 12,827 14,408 8,777 10,392 Dom 8.59 9.46 0.86
  1. Dom = Dominated by quadrivalent vaccine